Johnson & Johnson
Johnson & Johnson Adopts New By-Laws and Shareholder Approvals at 2024 Annual Meeting
Summary
Johnson & Johnson's Board of Directors approved new by-laws effective April 25, 2024, which include updates to shareholder meeting procedures, voting standards, director nominations, indemnification provisions, and other non-substantive changes. At the 2024 Annual Meeting of Shareholders, all 13 Director nominees were elected, the Say on Pay for executive compensation was approved, PricewaterhouseCoopers LLP was ratified as the independent auditor, and a shareholder proposal for gender-based compensation gaps was not approved.
Profitelligence Alerts
Get alerts for JNJ
Be first to know when Johnson & Johnson files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Johnson & Johnson
Johnson & Johnson is a multinational corporation engaged in the research, development, production, and sale of a broad range of healthcare products. Primarily known for its pharmaceuticals, medical devices, and consumer health products, Johnson & Johnson has a significant presence in the global healthcare industry. It develops medications for a variety of fields such as immunology, oncology, neurology, infectious diseases, and vaccines. The company also produces a wide array of medical devices for surgery, orthopedics, and cardiovascular health. In addition to pharmaceuticals, Johnson & Johnson is renowned for its consumer health products, including baby care, skin and hair care, wound care, and over-the-counter pharmaceuticals, with well-recognized brands like Band-Aid, Tylenol, and Neutrogena. Operating globally, the corporation's extensive portfolio and commitment to healthcare innovation make it a pivotal player in the industry, ensuring it remains influential in addressing worldwide health challenges and advancing medical technology.
Official SEC Documents
Advertisement